~ Buy the VOQUEZNA TRIPLE PAK (amoxicillin; clarithromycin; vonoprazan fumarate) Drug Profile, 2024 PDF Report in the Report Store ~

VOQUEZNA TRIPLE PAK Drug Patent Profile

When do Voquezna Triple Pak patents expire, and what generic alternatives are available?

Voquezna Triple Pak is a drug marketed by Phathom and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and three patent family members in forty-three countries.

The generic ingredient in VOQUEZNA TRIPLE PAK is amoxicillin; clarithromycin; vonoprazan fumarate. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; clarithromycin; vonoprazan fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Voquezna Triple Pak

Voquezna Triple Pak will be eligible for patent challenges on May 3, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 3, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VOQUEZNA TRIPLE PAK

International Patents:	103
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for VOQUEZNA TRIPLE PAK
DailyMed Link:	VOQUEZNA TRIPLE PAK at DailyMed

See drug prices for VOQUEZNA TRIPLE PAK

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VOQUEZNA TRIPLE PAK

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

NDA:

215152

Dosage:

CAPSULE, TABLET, TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VOQUEZNA TRIPLE PAK

VOQUEZNA TRIPLE PAK is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Phathom	VOQUEZNA TRIPLE PAK	amoxicillin; clarithromycin; vonoprazan fumarate	CAPSULE, TABLET, TABLET;ORAL	215152-001	May 3, 2022		RX	Yes	Yes				Y
Phathom	VOQUEZNA TRIPLE PAK	amoxicillin; clarithromycin; vonoprazan fumarate	CAPSULE, TABLET, TABLET;ORAL	215152-001	May 3, 2022		RX	Yes	Yes
Phathom	VOQUEZNA TRIPLE PAK	amoxicillin; clarithromycin; vonoprazan fumarate	CAPSULE, TABLET, TABLET;ORAL	215152-001	May 3, 2022		RX	Yes	Yes			Y
Phathom	VOQUEZNA TRIPLE PAK	amoxicillin; clarithromycin; vonoprazan fumarate	CAPSULE, TABLET, TABLET;ORAL	215152-001	May 3, 2022		RX	Yes	Yes

International Patents for VOQUEZNA TRIPLE PAK

When does loss-of-exclusivity occur for VOQUEZNA TRIPLE PAK?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Japan

Malaysia

Mexico

Morocco

New Zealand

Peru

Singapore

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VOQUEZNA TRIPLE PAK around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1111922
Morocco	32556	تركيب صيدلاني
European Patent Office	2564833	Composition pharmaceutique stabilisée à la lumière (Photostabilized pharmaceutical composition)
Brazil	PI0916689	composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
Taiwan	I358296
Japan	5593363

VOQUEZNA TRIPLE PAK Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for VOQUEZNA TRIPLE PAK

Introduction

VOQUEZNA TRIPLE PAK, along with VOQUEZNA and VOQUEZNA DUAL PAK, is a novel treatment for gastroesophageal reflux disease (GERD) developed by Phathom Pharmaceuticals. This drug has been making significant strides in the market since its launch, and its financial performance is a key indicator of its success.

Market Adoption and Prescription Trends

The market adoption of VOQUEZNA TRIPLE PAK has been robust. As of October 25, 2024, over 143,000 prescriptions for VOQUEZNA products, including VOQUEZNA TRIPLE PAK, have been filled, representing a 138% increase from the 60,000 prescriptions filled as of the last quarterly report[1][3][5].

Sequential Growth

The third quarter of 2024 saw a nearly doubling of prescriptions filled compared to the second quarter, with over 69,000 prescriptions for VOQUEZNA products filled in the third quarter, up from approximately 35,000 in the second quarter[1][3][5].

Expanding Prescriber Base

The prescriber base for VOQUEZNA has also expanded significantly. As of October 18, 2024, the number of cumulative prescribers grew to more than 13,600, an increase of over 65% from the 8,200 prescribers reported in the previous quarter[5].

Commercial Coverage and Access

Phathom Pharmaceuticals has secured broad and favorable commercial coverage for VOQUEZNA products. As of the third quarter 2024, commercial access for VOQUEZNA tablets covers over 80% of U.S. commercial lives, and the coverage now reaches an estimated 120 million U.S. commercially covered lives[3][5].

Label Expansion

A significant factor contributing to the strong market adoption is the label expansion of VOQUEZNA to include Non-Erosive GERD in July 2024. This expansion has greatly increased the market opportunity for the drug, highlighting the high unmet need in GERD treatment[1][3][5].

Financial Performance

Revenue

Net revenues for the third quarter 2024 were $16.4 million, related to sales of VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. This represents a substantial increase from the $7.3 million in revenue reported for the second quarter 2024, marking a over 120% sequential quarterly increase[1][3][5].

Research and Development (R&D) Expenses

R&D expenses for the third quarter 2024 decreased to $8.7 million, down from $12.3 million in the third quarter 2023. This decrease is attributed to lower clinical trial expenses following the wrap-up of activities related to the PHALCON-NERD-301 daily dosing study[1][3][5].

Selling, General and Administrative (SG&A) Expenses

SG&A expenses for the third quarter 2024 increased significantly to $76.1 million, up from $23.4 million in the third quarter 2023. This increase is due to higher personnel costs and increased activity related to the buildout of commercial infrastructure and marketing efforts in support of the VOQUEZNA launch[1][3][5].

Net Loss

Despite the revenue growth, Phathom Pharmaceuticals reported a net loss of $85.6 million for the third quarter 2024, compared to a net loss of $43.2 million for the third quarter 2023. This is largely due to the increased SG&A expenses associated with the commercial launch and marketing activities[1][3][5].

Funding and Financial Strength

Phathom Pharmaceuticals has strengthened its financial position with a successful $130 million equity raise. This funding will support further investment in the growth of the VOQUEZNA brand and reinforce the company's ability to capitalize on the drug's blockbuster potential[3].

Market Sentiment and Competitive Position

The strong demand for VOQUEZNA products, coupled with favorable payer coverage and expanding commercial access, validates Phathom's launch strategies. VOQUEZNA is positioned to potentially displace standard proton pump inhibitors (PPIs) as a treatment for GERD, indicating a promising competitive position in the market[3].

Key Takeaways

• Robust Market Adoption: Over 143,000 prescriptions for VOQUEZNA products have been filled, with a significant increase in sequential growth.
• Expanding Prescriber Base: The number of prescribers has grown to over 13,600, indicating strong physician and patient demand.
• Broad Commercial Coverage: VOQUEZNA now covers over 80% of U.S. commercial lives, reaching an estimated 120 million covered lives.
• Financial Growth: Net revenues for the third quarter 2024 were $16.4 million, with a substantial increase from the previous quarter.
• Label Expansion: The inclusion of Non-Erosive GERD in the label has expanded the market opportunity for VOQUEZNA.
• Financial Strength: A successful $130 million equity raise has strengthened Phathom's financial position to support further brand growth.

FAQs

What is VOQUEZNA TRIPLE PAK?

VOQUEZNA TRIPLE PAK is a novel, first-in-class potassium-competitive acid blocker (PCAB) used for the treatment of gastroesophageal reflux disease (GERD).

How has the market adoption of VOQUEZNA TRIPLE PAK been?

The market adoption has been robust, with over 143,000 prescriptions filled as of October 25, 2024, representing a 138% increase from the previous quarter.

What was the revenue for VOQUEZNA products in the third quarter 2024?

Net revenues for the third quarter 2024 were $16.4 million, marking a over 120% sequential quarterly increase.

What factors have contributed to the strong market performance of VOQUEZNA?

The label expansion to include Non-Erosive GERD, broad commercial coverage, and strong demand from physicians and patients have all contributed to the drug's success.

How has Phathom Pharmaceuticals' financial position been strengthened?

A successful $130 million equity raise has strengthened the company's financial position, enabling further investment in the growth of the VOQUEZNA brand.

Sources

1. Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results - Investors.phathompharma.com
2. Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update - Investors.phathompharma.com
3. Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates - Biospace.com
4. CORPORATE OVERVIEW - Public now
5. Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results - Investors.phathompharma.com (PDF)